Form 4: APPLIED DNA SCIENCES Director Acquires 22,511 Shares

APPLIED DNA SCIENCES INC Director Yacov Shamash acquired 22,511 shares of common stock through a restricted stock unit grant.

Summary

• Yacov A. Shamash, a Director of APPLIED DNA SCIENCES INC (BNBX), acquired 22,511 shares of common stock.
• The transaction occurred on October 17, 2025, and was reported on October 20, 2025.
• The shares were acquired at a price of $0, indicating a grant of restricted stock units (RSUs).
• Following this transaction, Yacov A. Shamash beneficially owns a total of 22,512 shares of common stock directly.
• The restricted stock units are scheduled to vest 100% upon 90 days from the date of grant.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase or sale plan.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While it's a compensation grant rather than an open market purchase, it still represents an increase in insider ownership and aligns the director's interests with shareholders. The pre-scheduled nature via a 10b5-1 plan makes it a routine event.

Positives

• The acquisition of shares by a director, even as a grant, aligns management's interests with those of shareholders.
• The grant of restricted stock units at a $0 price is a form of equity compensation, incentivizing long-term performance.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the vesting schedule of the granted restricted stock units.

Industry Context

This insider transaction is a routine compensation event and does not directly reflect broader industry trends or competitive positioning. It is a standard practice for companies to grant equity compensation to directors to align their interests with shareholders.

Comparison to Industry Standards

• Granting restricted stock units as part of director compensation is a common practice across various industries, aligning with corporate governance best practices to incentivize long-term commitment and performance.
• The use of a Rule 10b5-1 plan for such grants is also standard, providing an affirmative defense against insider trading allegations by demonstrating that the transaction was pre-scheduled.

Related Party Transactions

• The acquisition of shares by a director is considered a related party transaction, as it involves an insider of the company.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, signaling confidence in the company's future, although this is a compensation grant rather than an open market purchase.
• Management/Directors: The grant of restricted stock units serves as an incentive for the director, aligning their financial interests with the company's long-term performance.

Next Steps

• The 22,511 restricted stock units are expected to vest 100% approximately 90 days from the grant date of October 17, 2025, which is around January 15, 2026.

Key Dates

Keywords

APPLIED DNA SCIENCES, BNBX, Insider Transaction, Form 4, Restricted Stock Units, Equity Compensation, Director Shareholding, Yacov Shamash